NO20044749L - Stabilisert naturlig cannabinoidformulering - Google Patents

Stabilisert naturlig cannabinoidformulering

Info

Publication number
NO20044749L
NO20044749L NO20044749A NO20044749A NO20044749L NO 20044749 L NO20044749 L NO 20044749L NO 20044749 A NO20044749 A NO 20044749A NO 20044749 A NO20044749 A NO 20044749A NO 20044749 L NO20044749 L NO 20044749L
Authority
NO
Norway
Prior art keywords
sugar
drying
natural cannabinoid
mixture
cannabinoid formulation
Prior art date
Application number
NO20044749A
Other languages
English (en)
Norwegian (no)
Inventor
Henderik W Frijlink
Anko Eissens
Dirk J Van Drooge
Wouter L J Hinrichs
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20044749L publication Critical patent/NO20044749L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20044749A 2002-04-03 2004-11-02 Stabilisert naturlig cannabinoidformulering NO20044749L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36961302P 2002-04-03 2002-04-03
EP02076339 2002-04-04
PCT/EP2003/050087 WO2003082246A1 (en) 2002-04-03 2003-04-02 Stabilized natural cannabinoid formulation

Publications (1)

Publication Number Publication Date
NO20044749L true NO20044749L (no) 2005-01-03

Family

ID=28676390

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044749A NO20044749L (no) 2002-04-03 2004-11-02 Stabilisert naturlig cannabinoidformulering

Country Status (16)

Country Link
EP (1) EP1492503B1 (pl)
JP (1) JP4491241B2 (pl)
CN (1) CN100592903C (pl)
AT (1) ATE413862T1 (pl)
AU (1) AU2003240759B2 (pl)
BR (1) BR0308779A (pl)
CA (1) CA2480270A1 (pl)
DE (1) DE60324668D1 (pl)
DK (1) DK1492503T3 (pl)
ES (1) ES2316759T3 (pl)
HR (1) HRP20040816A2 (pl)
MX (1) MXPA04009673A (pl)
NO (1) NO20044749L (pl)
PL (1) PL209134B1 (pl)
RU (1) RU2311178C2 (pl)
WO (1) WO2003082246A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
BR112012024432A2 (pt) 2010-03-29 2016-05-31 Ferring Bv composição farmacêutica de dissolução rápida
JP6174585B2 (ja) 2011-09-16 2017-08-02 フェリング ベスローテン フェンノートシャップ 速溶性医薬組成物
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
JP6953414B2 (ja) * 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
CA3106476A1 (en) * 2018-07-10 2020-01-16 Cardinal Advisory Limited Formulation of cannabinoid compounds
CN110200953B (zh) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
CA3128696C (en) * 2020-08-21 2023-09-26 Organigram Inc. Buccal dosage forms comprising oligosaccharides
WO2023224960A1 (en) * 2022-05-17 2023-11-23 Orcosa Inc. Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
NL1012300C2 (nl) * 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.

Also Published As

Publication number Publication date
CA2480270A1 (en) 2003-10-09
CN1642527A (zh) 2005-07-20
BR0308779A (pt) 2004-12-28
RU2311178C2 (ru) 2007-11-27
HK1078458A1 (zh) 2006-03-17
DE60324668D1 (de) 2008-12-24
PL209134B1 (pl) 2011-07-29
JP2005521710A (ja) 2005-07-21
DK1492503T3 (da) 2009-03-09
WO2003082246A1 (en) 2003-10-09
JP4491241B2 (ja) 2010-06-30
EP1492503B1 (en) 2008-11-12
ATE413862T1 (de) 2008-11-15
AU2003240759B2 (en) 2008-02-14
CN100592903C (zh) 2010-03-03
EP1492503A1 (en) 2005-01-05
ES2316759T3 (es) 2009-04-16
MXPA04009673A (es) 2005-01-11
AU2003240759A1 (en) 2003-10-13
HRP20040816A2 (en) 2005-06-30
PL372921A1 (pl) 2005-08-08
RU2004132190A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
Gadzovska et al. Jasmonic acid elicitation of Hypericum perforatum L. cell suspensions and effects on the production of phenylpropanoids and naphtodianthrones
Pastrana-Bonilla et al. Phenolic content and antioxidant capacity of muscadine grapes
NO20012610L (no) Derivat av kardanol og anvendelser derav
NO20071610L (no) Immunogen sammensetning
DK0725642T3 (da) Stabiliseret prostaglandin E1
NO20051998L (no) Torke prosess
HUP9901716A2 (hu) Eljárás anyagoknak száraz, habosított üvegekbe történő stabil beépítésére és az így előállított kompozíciók
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
HU9904549A (en) Vaccines
NO954329L (no) Forbedrede farmasöytisk akseptable blandinger inneholdende en alkohol og et hydrofobt legemiddel
ES2176502T3 (es) Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion.
NO942899L (no) Stabiliserte, radiofarmasöytiske sett
ATE413862T1 (de) Stabilisierte natürliche cannabinoid formulierung
KR910000709A (ko) 온단세트론 염산염 이수화물 결정의 입도 감소법
NO922246L (no) Matvare-modifiserende preparat og fremgangsmaate for fremstilling derav
DK1032391T3 (da) Sfæroider indeholdende tiagabin, fremstillingsproces og farmaceutisk sammensætning
Debiasi et al. Phytochemical screening of Cordia glabrata (MART.) A. DC. extracts and its potential antioxidant, photoprotective, antimicrobial and antiviral activities
Kimel et al. Hplc-Dad-Esi/Ms Analysis of Arnica Tm Constituents
Rocha-Parra et al. Chemical characterization of an encapsulated red wine powder and its effects on neuronal cells
Briggs α-Amylase in germinating, decorticated barley—I: α-Amylase, conditions of growth, and grain constituents
Brikenstein et al. Optimization of trimming techniques for enhancing cannabinoid and terpene content in medical Cannabis inflorescences
NO912118D0 (no) Avgrenet araban og dets anvendelse som fetterstatning.
Wirtz et al. Tyrosine and phenylalanine concentrations in haemolymph and tissues of the American cockroach, Periplaneta americana, during metamorphosis
Santhosh et al. Aldose reductase and advanced glycation end products formation inhibitory activity of standardized extracts of Picrorhiza kurroa (Royle ex benth) and Hibiscus rosa-sinensis (Linn.)
Neitz et al. Changes in the Protein Pattern in the Salivary Glands of Paralŷsis inducing female Rhipicephalus evertsi evertsi during Infestation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application